Trevor Hallam

CSO at Sail Biomedicines

Speaker

Trevor Hallam, Ph.D., is Chief Scientific Officer of Laronde, the company pioneering Endless RNA™ (eRNA) – a novel, engineered form of RNA that can be programmed to express proteins inside the body for breakthrough treatments.

Before joining Laronde, Trevor served as President, Research and Chief Scientific Officer at Sutro Biopharma, a clinical stage company focused on next-generation cancer therapeutics. At Sutro, Trevor was instrumental in the transformation of Sutro’s cell-free protein synthesis platform from an early technology platform into a clinical-stage, multi-modality platform with proven manufacturing capability. Prior to joining Sutro, Trevor was Executive Vice President of R&D at Palatin Technologies, Inc., and held several senior management positions in various major pharmaceutical companies over 20 years, including AstraZeneca, Roche, and Glaxo SmithKline. Trevor is a member of the Scientific Advisory Board for Sutro Biopharma.

Trevor received a BSc (Hons) in Biochemistry from the University of Leeds and a Ph.D. in Biochemistry from Kings College, University of London. He then conducted post-doctoral training at the Physiological Laboratory, University of Cambridge.